Keryx Biopharmaceuticals (KERX) Ramps 38% Upon Trade Resumption

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 9/2/2026

1. GTLB
2. PANW
3. DELL
4. MDB
5. MMED

6. CRDO
7. GFS
8. NVDA
9. SPY
10. NIO

January 28, 2013 7:41 AM EST

Price: $3.36 --0%

Overall Analyst Rating:
SELL (= Flat)

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) resumed trading and is higher by 38 percent following positive Phase 3 trial data.

Sign up for StreetInsider Free!

Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!